[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 92 of about 92
1. Cluzeau T, Mounier N: [Patients and the Web]. Bull Cancer; 2010 Oct;97(10):1133-6
MedlinePlus Health Information. consumer health - Evaluating Health Information.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV infection is an infection highly publicized in recent years, we take the case of Hodgkin's disease associated with HIV to compare data from the Internet and scientific articles.
  • [MeSH-major] Information Dissemination / methods. Internet / standards. Lymphoma, AIDS-Related. Medical Informatics Applications. Patient Education as Topic / standards
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Drug Therapy, Combination / methods. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663740.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


2. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas in Nigeria.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
  • We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
  • Since January 1993 to the present, all patients with haematologic cancers are routinely screened (following appropriate counseling) for HIV infection.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • Nine patients (2.3%) were confirmed to be HIV- positive, all within the age bracket 24-60 (median = 50) years.
  • None of the patients with HL and BL were HIV positive.
  • Patients with NHL presented at advanced stage of the disease (at least clinical stage IIIb), and all those with CLL presented at stage C of the International Working Party Classification.
  • All the HIV-positive patients with NHL succumbed to the disease within one to three weeks of admission into the hospital.
  • The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • All the patients presented at a very advanced stage of the disease with significantly shortened survival.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.
  • Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.
  • These findings were not related to age, sex or type of lymphoma.
  • There was no association of HHV-8 with the lymphoma cells.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


Advertisement
4. Corti M, Carolis LD, Solari R, Villafañe MF, Schtirbu R, Lewi D, Narbaitz M: Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature. Braz J Infect Dis; 2010 Jan-Feb;14(1):81-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.
  • Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.
  • Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.
  • Here, we are presenting 5 patients with cutaneous involvement in the setting of HIV/AIDS disease.
  • Two of them were primary cutaneous non-Hodgkin lymphomas.
  • All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428660.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Orem J, Fu P, Ness A, Mwanda WO, Remick SC: Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease. East Afr Med J; 2005 Sep;82(9 Suppl):S144-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease.
  • OBJECTIVES: To determine the effectiveness of an oral combination chemotherapy regimen administered to patients with AIDS-associated Hodgkin's disease.
  • MAIN OUTCOME MEASURES: Clinical demographic variables, peripheral blood counts, serum chemistries, CD4 lymphocyte count, histopathological subtype of Hodgkin's disease were identified for all patients, who were staged according to Ann Arbor criteria.
  • CONCLUSIONS: This feasibility study demonstrates acceptable tolerance and excellent clinical activity of oral combination chemotherapy in patients with AIDS-associated Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619690.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


6. Pereg D, Koren G, Lishner M: The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy. Haematologica; 2007 Sep;92(9):1230-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.
  • BACKGROUND AND OBJECTIVES: Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries.
  • DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries.
  • The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.
  • RESULTS: Chemotherapy and radiotherapy during the first trimester are associated with increased risk of congenital malformations and this risk diminishes as pregnancy advances.
  • In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended.
  • In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkins lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation.
  • INTERPRETATION AND CONCLUSIONS: When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.
  • [MeSH-major] Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666365.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 67
  •  go-up   go-down


7. Wood C, Harrington W Jr: AIDS and associated malignancies. Cell Res; 2005 Nov-Dec;15(11-12):947-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and associated malignancies.
  • AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression.
  • Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative disease.
  • In the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-1 infection have decreased in developed nations where ARV is administered, but still poses a major problem in developing countries where HIV-1 incidence is high and ARV is still not yet widely available.
  • Even in ARV treated individuals there is a concern that the prolonged survival of many HIV-1 carriers is likely to eventually result in an increased number of malignancies diagnosed.
  • Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • The incidence of NHL has increased nearly 200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.
  • These AIDS related lymphomas are distinct from their counterparts seen in HIV-1 seronegative patients.
  • For example nearly half of all cases of ARL are associated with the presence of a gamma herpesvirus, Epstein Barr virus (EBV) or human herpesvirus-8 (HHV-8)/ Kaposi's sarcoma associated herpesvirus (KSHV).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. HIV / physiology. Neoplasms / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354573.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082274; United States / NCI NIH HHS / CA / CA76958; United States / NICHD NIH HHS / HD / HD39620; United States / NCRR NIH HHS / RR / RR15635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] China
  • [Number-of-references] 60
  •  go-up   go-down


8. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC: Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol; 2009 Jul 20;27(21):3480-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
  • PURPOSE Africa is burdened by the AIDS epidemic and attendant increase in HIV/AIDS-related malignancies.
  • Dose-modified oral chemotherapy for AIDS-related non-Hodgkin's lymphoma is one such approach.
  • PATIENTS AND METHODS The oral regimen consisted of lomustine 50 mg/m(2) on day 1 (cycle 1 only), etoposide 100 mg/m(2) on days 1 to 3, and cyclophosphamide/procarbazine 50 mg/m(2) each on days 22 to 26 at 6-week intervals (one cycle) for two total cycles in HIV-infected patients with biopsy-proven non-Hodgkin's lymphoma.
  • The majority of patients were female (59%) and had a poor performance status (63%); 69% of patients had advanced-stage disease; and 18 patients (37%) had access to antiretroviral therapy.
  • The regimen was well tolerated, had modest effects (decline) on CD4(+) lymphocyte counts (P = .077), and had negligible effects on HIV-1 viral replication.
  • Four febrile neutropenia episodes and three treatment-related deaths (6% mortality rate) occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV-1 / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Africa South of the Sahara. Antiretroviral Therapy, Highly Active / trends. CD4 Lymphocyte Count. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. HIV Infections / complications. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation. Humans. Kenya. Lomustine / therapeutic use. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Uganda. Virus Replication / drug effects. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):532-40 [14595710.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Am J Med. 1986 Jan;80(1):119-22 [3942143.001]
  • [Cites] Ann Intern Med. 1989 Jun 1;110(11):937-40 [2719427.001]
  • [Cites] Rev Infect Dis. 1989 Nov-Dec;11(6):954-63 [2690289.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(4):430-7 [2313564.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Blood. 1993 May 15;81(10):2810-5 [8490187.001]
  • [Cites] Drugs. 1999;58 Suppl 3:99-107 [10711848.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:362-6 [11131726.001]
  • [Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Biometrics. 1999 Jun;55(2):625-9 [11318225.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):609-15 [11771676.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):718-32 [12011222.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] AIDS. 1998;12 Suppl 1:S3-14 [9677185.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):245-50 [15547922.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):133-45 [15829373.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S155-60 [16619692.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):398-403 [18385682.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19470940.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / TW00011; United States / NCI NIH HHS / CA / R01 CA083528; United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA83528; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA066531; United States / NCI NIH HHS / CA / CA43703; United States / FIC NIH HHS / TW / D43 TW000011; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / U01 CA066531; United States / NIAID NIH HHS / AI / P30 AI036219
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2717754
  •  go-up   go-down


9. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


10. Cheung MC, Hicks LK, Leitch HA: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):E22-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is the second most common non-AIDS-defining malignancy among persons infected with HIV, and its incidence might be increasing in the current era of combination antiretroviral therapy (cART).
  • Antiretroviral therapy is commonly prescribed concomitantly with chemotherapy in the treatment of AIDS-related malignancies.
  • In particular, the potential for excessive vinca alkaloid-associated toxicity is significant, given the metabolism of drugs such as vinblastine by the 3A4 isoenzyme of the cytochrome P450 system and the inhibition of this isoenzyme by protease inhibitors.
  • We report 3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease. Lymphoma, AIDS-Related


11. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


12. Bosch Príncep R, Lejeune M, Salvadó Usach MT, Jaén Martínez J, Pons Ferré LE, Alvaro Naranjo T: Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol; 2005 Oct;84(10):661-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
  • This study aimed to assess the differences in the cellular composition of the inflammatory reactive background around tumoral cells of classical Hodgkin's lymphomas (cHL) inside and outside the HIV settings.
  • Sections from paraffin-embedded tumor samples from nine HIV-infected cHL patients were immunostained, using standard immunohistochemical protocols and were compared to a control group of 90 HIV-noninfected cHL patients.
  • Our clinical and histological data indicate that HIV-infected cHL patients present a higher frequency of mixed cellularity (MC) histological subtypes, more advanced disease stages, a poor response to treatment, and a poor overall survival compared to control patients.
  • The inflammatory infiltrate of HIV-infected patients had a significant reduction of CD4+ T lymphocytes (CD4/CD8 ratio 1:23), a decrease in infiltrating GrB+ cells (activated cytotoxic cells) and an increase in infiltrating TIA+ T cells (mainly nonactivated cytotoxic cells) in these patients (GrB/TIA-1 ratio 1:12).
  • In conclusion, this study highlights an important intratumoral loss of CD4+ T cells (striking inversion in the CD4/CD8 ratio) and a decrease in intratumoral activated cytotoxic T lymphocytes in HIV-associated cHL patients.
  • Further studies are required to confirm these results and to determine the role of these findings on the antitumoral immune response observed in HIV-associated cHL.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / metabolism. HIV. HIV Infections / metabolism. Hodgkin Disease / metabolism. Serine Endopeptidases / metabolism


13. Berenguer J, Miralles P, Ribera JM, Rubio R, Valencia E, Mahillo B, Pintado V, Palacios R, Montes ML, Téllez MJ, La Cruz J, Torre-Cisneros J, Rodríguez-Arrondo F, Sepúlveda MA, Gutiérrez F, Peralta G, Boix V: Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr; 2008 Apr 1;47(4):422-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy.
  • OBJECTIVES: We analyzed survival, therapeutic response, and prognostic factors in patients with HIV-related Hodgkin lymphoma (HL) treated or not with highly active antiretroviral therapy (HAART).
  • Outcomes and prognostic factors of complete remission (CR), overall survival (OS), and disease-free survival (DFS) were assessed by an intention-to-treat analysis of all patients who received at least 1 chemotherapy course.
  • RESULTS: No differences were found between groups at baseline in the specific characteristics of HIV and HL.
  • Factors independently associated with CR by logistic regression analysis were appropriate-for-stage therapy of HL, HAART, and baseline CD4 count > or =100 cells/microL.
  • CR was the only factor independently associated with OS by Cox regression analysis.
  • CONCLUSIONS: The achievement of CR was independently associated with appropriate-for-stage therapy for HL, with HAART, and with a baseline CD4 count > or =100 cells/microL.
  • The only variable independently associated with OS was the achievement of CR.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy


14. Makinson A, Martelli N, Peyrière H, Turriere C, Le Moing V, Reynes J: Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol; 2007 Apr;78(4):358-60
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.
  • A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Neutropenia / chemically induced. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378895.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


15. Tserenpuntsag B, Kołacińska A, Jabłonowska E: [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)]. Przegl Epidemiol; 2007;61(3):529-34
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
  • [Transliterated title] Nowotwory zwiazane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART).
  • HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency.
  • Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies.
  • HAART widely used since 1996 changed the natural process of HIV infection by aggressively suppressing viral replication and progress of HIV disease.
  • It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers.
  • HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Female. Humans. Male. Remission Induction. Treatment Outcome


16. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


17. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
  • METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


18. Martí-Carvajal AJ, Cardona AF, Lawrence A: Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. Cochrane Database Syst Rev; 2009;(3):CD005419
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
  • BACKGROUND: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL).
  • OBJECTIVES: To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.
  • For additional information see the Cochrane HIV/AIDS Group search strategy.
  • SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated AIDS-related NHL.
  • Disease free survival (DFS) was reported in two of the four RCTs, but it was not statistically significant between treatment groups.
  • AUTHORS' CONCLUSIONS: We found no evidence that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Rituximab. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588373.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q573I9DVLP / Leucovorin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol; M-BACOD protocol; VAP-cyclo protocol
  • [Number-of-references] 112
  •  go-up   go-down


19. Djunic I, Jevtovic DL, Ranin J, Salemovic D, Tomin D, Mihaljevic B: Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma. Biomed Pharmacother; 2008 Jan;62(1):12-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: The majority of patients with AIDS-related non-Hodgkin's lymphoma (ARL) present with advanced disease, aggressive histological type, B-symptoms, and often with an extranodal localization.
  • Twenty-six patients had an aggressive type of lymphoma while 2 had an indolent type.
  • RESULTS: This study demonstrated that significant factors for OS in patients with ARL were the high International Prognostic Index (P=0.019), previous AIDS event (P=0.04), aggressive histological type of NHL (P=0.007) and extranodal disease (P=0.04).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Vincristine / administration & dosage. Yugoslavia

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629445.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


20. Palmieri C, Treibel T, Large O, Bower M: AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM; 2006 Dec;99(12):811-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.
  • Highly active antiretroviral therapy (HAART) has had a dramatic effect on the natural history of HIV disease, reducing the incidence of opportunistic infections and Kaposi's sarcoma, and improving overall survival.
  • Since HAART became available in 1996, the incidence of AIDS-related non-Hodgkin's lymphoma (NHL) has fallen, and although there has been no change in the clinical features at presentation, the overall survival of patients with AIDS-related NHL has improved.
  • Prognosis is now determined chiefly by lymphoma-associated factors similar to those in the general population (the International Prognostic Index), although serum CD4 count at lymphoma diagnosis is an additional independent prognostic factor.
  • The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Neutropenia / therapy. Sarcoma, Kaposi / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085516.001).
  • [ISSN] 1460-2725
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


21. Martí-Carvajal AJ, Cardona AF, Rodríguez ML: Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev; 2007;(2):CD006149
Genetic Alliance. consumer health - Hodgkin lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults.
  • BACKGROUND: Hodgkin's disease (HD) is the most common non-AIDS-defining malignancy in HIV-infected patients.
  • Its unusually aggressive tumour behaviour includes a higher frequency of unfavourable histologic subtypes, high-stage and extranodal involvement by the time of presentation (anal canal, stomach), and poor therapeutic outcome, in comparison with HD outside the HIV setting.
  • Thus, there is a need to identify the efficacy and safety of different interventions for AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • OBJECTIVES: To assess the effects of different interventions for treating AIDS-associated Hodgkin's disease including chemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • SEARCH STRATEGY: We searched The Cochrane HIV/AIDS Group Trials Register (September 2006), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings.
  • MAIN RESULTS: We were unable to find any randomised controlled trials of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • AUTHORS' CONCLUSIONS: Randomised controlled trials are needed to establish the efficacy and safety of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443616.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


22. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


23. Caimi PF, Barr PM, Berger NA, Lazarus HM: Non-Hodgkin's lymphoma in the elderly. Drugs Aging; 2010 Mar 1;27(3):211-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in the elderly.
  • The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin's lymphoma (NHL) makes this group of neoplasms an important and growing problem.
  • Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities.
  • The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.
  • Diffuse large B-cell lymphoma is an aggressive but potentially curable disease.
  • Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.
  • [MeSH-major] Aging / physiology. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / physiopathology. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210368.001).
  • [ISSN] 1179-1969
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


24. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, Chiarion-Sileni V, Monfardini S: Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol; 2005 Mar;53(3):253-65
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatments of AIDS-related Kaposi's sarcoma.
  • Although Kaposi's sarcoma (KS) has decreased in countries where the highly active antiretroviral therapy (HAART) regimen is available, however it remains, after non-Hodgkin's lymphomas, the most common malignancy in HIV+ patients.
  • Advances in the treatment of AIDS-KS have been achieved, even though a gold standard therapy has not been yet defined.
  • [MeSH-minor] Algorithms. Angiogenesis Inhibitors / therapeutic use. Antiviral Agents / therapeutic use. Disease Management. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718150.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antiviral Agents
  • [Number-of-references] 136
  •  go-up   go-down


25. Uriarte-Duque J, Hernández-Riverab G: [Treatment of non-Hodgkin's lymphoma associated with acquired immnodeficiency syndrome (AIDS) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán]. Gac Med Mex; 2006 Mar-Apr;142(2):99-102
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of non-Hodgkin's lymphoma associated with acquired immnodeficiency syndrome (AIDS) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán].
  • [Transliterated title] Tratamiento de pacientes con linfomas no Hodgkin asociados a SIDA: experiencia del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
  • BACKGROUND: Survival in patients with acquired immunodeficiency syndrome (AIDS) related non-Hodgkin's Lymphoma has improved with the use of High Active Antiretroviral Therapy (HAART) and less toxic chemotherapy.
  • MATERIAL AND METHODS: Clinical characteristics and outcome among patients treated for AIDS related non-Hodgkin's Lymphoma are described.
  • Overall survival (OS) and Free Disease Survival (FDS) using a Kaplan-Meier model were analyzed.
  • The overall Survival was 18 months and 13 month Free Disease Survival with a median follow-up of 16 months showing full response in 8/9 patients was observed.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711542.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


26. De Socio GV, Simonetti S, Rosignoli D, Minga P, Tomassini GM, Baldelli F: Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma. Int J STD AIDS; 2008 Oct;19(10):715-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma.
  • We describe a 42-year-old man with AIDS and Hodgkin's lymphoma whose severe and recalcitrant cutaneous warts resolved following treatment with local 1% cidofovir.
  • In advanced HIV disease complicated by additional haematological malignancy, cutaneous warts may be difficult to treat and present a challenge for the attending physicians.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. HIV Infections / complications. Hodgkin Disease / complications. Lymphoma, AIDS-Related / complications. Organophosphonates / administration & dosage. Warts / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824628.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


27. Diamond C, Taylor TH, Im T, Wallace M, Saven A, Anton-Culver H: How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma? Cancer Causes Control; 2007 Mar;18(2):135-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma?
  • OBJECTIVE: We sought to determine the accuracy of cancer registry data regarding the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) status of patients with non-Hodgkin's lymphoma (NHL).
  • METHODS: We used the population-based San Diego/Orange County cancer registry to identify 392 patients with HIV-related NHL diagnosed 1994-1999.
  • After matching for age, sex, race, period of NHL diagnosis, and hospital type, we were able to find 324 corresponding patients among the remaining 4,863 NHL patients diagnosed 1994-1999 (who did not have HIV infection according to cancer registry records).
  • We sought to review these patients' charts at 41 hospitals with 15 separate institutional review boards to determine if the HIV serostatus from the cancer registry was correct.
  • We performed a forward conditional multivariate logistic regression to determine characteristics associated with a false positive HIV status.
  • Compared to correctly identified patients, false positives were more likely to be > or =50 years old, female, and treated with chemotherapy and less likely to be single with high grade or extranodal disease.
  • CONCLUSION: Using cancer registry data to identify AIDS-related NHL is a valid research practice.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Medical Records / standards. Population Surveillance / methods. Registries / standards. SEER Program / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235495.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA96480
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


29. De Paoli P: Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets; 2008 Nov;8(7):591-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel virally targeted therapies of EBV-associated tumors.
  • EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplant lymphoproliferative disorders, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma.
  • EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991568.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 122
  •  go-up   go-down


30. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • Increased proportion of non-Hodgkin's lymphoma (NHL) was observed (PIR in males = 17.1, 95%CI 13.33-21.84, females = 10.3, 95%CI 6.10-17.41).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.
  • [MeSH-major] HIV Infections. Neoplasms / epidemiology. Registries


31. Foschi D, Rizzi A, Corsi F, Trabucchi E, Corbellino M: Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS). Dig Liver Dis; 2008 Jun;40(6):481-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS).
  • In the present article we describe a patient with AIDS and chylous ascites secondary to B-cell non Hodgkin's lymphoma.
  • A 43 years old homosexual HIV-positive man.
  • All blood tests and analysis of the peritoneal fluid with polymerase chain reaction for DNA sequence of broad-range bacterial Post Voiding Residual volume, Mycobacterium tuberculosis, Kaposi Sarcoma associated Herpes virus and Epstein Barr Virus were negative.
  • The final pathology report was of diffuse, CD20-positive, CD3-negative, Epstein Barr Virus-negative, large B-Cell non Hodgkin's lymphoma.
  • Five months after the initial diagnosis of lymphoma, the patient relapsed and was treated with high-dose BEAM (carmustine, etoposide, cytosine, arabinoside, melphalan) chemotherapy followed by CD34 stem-cell transplantations salvage therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Chylous Ascites / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Adult. HIV-1. Humans. Male. Paracentesis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chylous Ascites.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997372.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist; 2005 Jun-Jul;10(6):412-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
  • Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).
  • Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.
  • AIDS-related KS varies from minimal to fulminant disease.
  • Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.
  • In addition to HAART, excellent treatments exist for both localized disease (topical gel, radiotherapy, and intralesional therapy) and advanced disease (liposomal anthracyclines, paclitaxel).
  • Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.
  • The role of analogous treatments used in HIV-negative patients, including monoclonal antibodies and autologous stem cell transplantation, requires further clarification in HIV-positive patients.
  • HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.
  • Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.
  • This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy


33. Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H: [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]. Med Mal Infect; 2006 Mar;36(3):157-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
  • OBJECTIVES: The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.
  • PATIENTS AND METHODS: A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-related lymphomas.
  • A high proportion of aggressive and disseminated disease was observed among NHL cases.
  • The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis).
  • CONCLUSIONS: The incidence of lymphomas in HIV-infected patients has not decreased since the introduction of HAART.
  • Immune restoration in lymphoma-free patients under HAART is poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Hodgkin Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome


34. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.
  • SUMMARY: The burden of neoplastic complications of HIV infection and endemic virus-associated tumors are assuming increasing significance in Africa.
  • [MeSH-major] HIV Infections / complications. Neoplasms / epidemiology. Neoplasms / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


35. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


36. Navarro CM, Shibli JA, Ferrari RB, d'Avila S, Sposto MR: Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome. J Periodontol; 2008 Mar;79(3):562-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome.
  • BACKGROUND: Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative malignancies that may be associated with acquired immunodeficiency syndrome (AIDS).
  • This report presents and discusses two unusual cases of gingival primary extranodal non-Hodgkin's lymphoma (PE-NHL) as the first manifestation of AIDS.
  • The patients were tested for human immunodeficiency virus (HIV) infection.
  • RESULTS: The clinicopathological evaluation and the serological HIV examination of the patients led us to the final diagnosis of gingival PE-NHL as the first manifestation of AIDS.
  • Both patients were referred to an oncologist and to an infectious disease specialist and were given antineoplastic chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Gingival Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315441.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


38. Knysz B, Kuliszkiewicz-Janus M, Jeleń M, Podlasin R, Gładysz A: Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients. Postepy Hig Med Dosw (Online); 2006;60:547-51
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients.
  • Combination antiretroviral therapy (cART) can improve immune system function through suppression of HIV-1 replication.
  • IRS can develop within weeks to months after cART is commenced and the time is related to the type of the disease.
  • There are but scant reports concerning IRS-NHL (non-Hodgkin's lymphoma) in HIV-1 positive subjects.
  • There was prompt progression of the disease and the outcome was fatal in all cases.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060896.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


39. Silverberg MJ, Abrams DI: AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol; 2007 Sep;19(5):446-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.
  • PURPOSE OF REVIEW: Effective antiretroviral therapy use has resulted in a large number of older individuals living with HIV.
  • Recent literature is reviewed with respect to the incidence and risk factors for cancer in HIV patients.
  • RECENT FINDINGS: Previous studies have demonstrated substantial declines in AIDS-defining malignancies in the era of antiretroviral therapy, with clear links to better immune function.
  • Increases in non-AIDS-defining malignancies such as Hodgkin's disease, skin, lung, anal, and kidney cancers have been noted by some but not all authors.
  • Certain non-AIDS-defining malignancies may be related to immunodeficiency, although data are conflicting.
  • Recent studies have indicated that confounding by traditional risk factors, including cigarette use, may account for some of the increased risk of lung and other cancers in HIV patients.
  • SUMMARY: Non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies in the antiretroviral therapy era.
  • Traditional risk factors play a significant role in the increased risk of non-AIDS-defining malignancies for HIV-infected individuals, but do not entirely explain the excess cancer risk.
  • Unanswered questions remain including the relationship of immunodeficiency and the risk of site-specific non-AIDS-defining malignancies, and the effect of antiretroviral therapy duration and drug class on cancer risk.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762569.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 67
  •  go-up   go-down


40. Langner-Wegscheider BJ, ten Dam-van Loon N, Mura M, Faridpooya K, de Smet MD: Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis. Can J Ophthalmol; 2010 Apr;45(2):157-60
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis.
  • OBJECTIVE: To report and evaluate intravitreal ganciclovir injections in non-AIDS patients with human cytomegalovirus (HCMV) retinitis.
  • PARTICIPANTS: Two SLE patients and one patient post chemotherapy for a non Hodgkin's lymphoma presented with myelosuppression and persistent cytomegalovirus retinitis despite systemic ganciclovir therapy.
  • One patient had persistent smouldering disease and reached quiescence using an intravitreal ganciclovir implant.


41. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 1;24(25):4123-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.
  • This multicenter phase II trial evaluated the response rate and disease-free survival after six courses of rituximab plus CHOP.
  • Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).
  • Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.
  • CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]
  • (PMID = 16896005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


42. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • DESIGN AND METHODS: From January 1996 to December 2005, 62 HIV-infected patients with newly diagnosed HL were treated in 15 Spanish hospitals.
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


43. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.
  • [MeSH-major] HIV Infections / complications. Immunosuppression / adverse effects. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


44. Guidoboni M, Ponzoni M, Caggiari L, Lettini AA, Vago L, De Re V, Gloghini A, Zancai P, Carbone A, Boiocchi M, Dolcetti R: Latent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma. J Virol; 2005 Feb;79(4):2643-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Latent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma.
  • We herein demonstrate that LMP-1 deletion mutants are highly associated with human immunodeficiency virus-related Hodgkin's lymphoma (HIV-HL) of Italian patients (29 of 31 cases; 93.5%), a phenomenon that is not due to a peculiar distribution of EBV strains in this area.
  • In fact, although HIV-HL patients are infected by multiple EBV variants, we demonstrate that LMP-1 deletion mutants preferentially accumulate within neoplastic tissues.
  • Subcloning and sequencing of the 3' LMP-1 ends of two HIV-HL genes in which both variants were present showed the presence of molecular signatures suggestive of a likely derivation of the LMP-1 deletion mutant from a nondeletion ancestor.
  • This phenomenon likely occurs within tumor cells in vivo, as shown by the detection of both LMP-1 variants in single microdissected Reed-Sternberg cells, and may at least in part explain the high prevalence of LMP-1 deletions associated with HIV-HL.
  • [MeSH-major] Carrier Proteins / metabolism. Herpesviridae Infections / virology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / metabolism. Hodgkin Disease / virology. Lymphoma, AIDS-Related / pathology. Reed-Sternberg Cells / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Dec;28(12):1408-14 [9416698.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):449-51 [10404102.001]
  • [Cites] Curr Biol. 1998 Mar 12;8(6):R196-8 [9512412.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):129-36 [9792299.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] J Virol. 2000 Aug;74(16):7610-8 [10906215.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):235-42 [11426545.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):250-5 [12949802.001]
  • [Cites] Lancet. 1989 Jun 24;1(8652):1458 [2567472.001]
  • [Cites] J Gen Virol. 1991 Oct;72 ( Pt 10):2399-409 [1681026.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2131-40 [1331932.001]
  • [Cites] Leukemia. 1993 Apr;7(4):580-5 [8464236.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):240-9 [9935206.001]
  • [Cites] J Infect Dis. 1999 Apr;179(4):763-74 [10068570.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1073-9 [8386441.001]
  • [Cites] Oncogene. 1993 Jun;8(6):1575-83 [8389032.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3372-81 [8389616.001]
  • [Cites] Blood. 1993 Nov 15;82(10):2937-42 [8219183.001]
  • [Cites] Eur J Cancer. 1994;30A(1):84-8 [8142171.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4053-60 [7994023.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):561-7 [7741100.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] Lab Invest. 1996 Oct;75(4):575-88 [8874388.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1723-31 [9057656.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):912-7 [9291815.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):239-50 [9322886.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • (PMID = 15681466.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / PDLIM7 protein, human
  • [Other-IDs] NLM/ PMC546537
  •  go-up   go-down


45. Tanaka PY, Pracchia LF, Calore EE: Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil. Int J Hematol; 2006 Nov;84(4):337-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
  • The relative risk of non-Hodgkin's lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV) is elevated compared with the general population.
  • We describe a retrospective study of 78 HIV-infected patients with NHL treated between 1999 and 2006 at the Infectology Institute, a reference center for HIV treatment in São Paulo, Brazil.
  • A univariate analysis showed a significant CR rate in patients with respect to the following factors: no acquired immunodeficiency syndrome (AIDS) diagnosis prior to the lymphoma, disease stage of I to II, and an International Prognostic Index (IPI) of low or low-intermediate risk.
  • A multivariate analysis indicated that only a previous AIDS diagnosis and the IPI were significantly related to the CR rate.
  • A median disease-free survival (DFS) time for the patients who achieved a CR was not reached, with a mean survival time of 73 months and a 3-year DFS rate of 77.5%.
  • Our results provide additional information regarding HIV-related lymphoma in Brazil.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Brazil. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisolone. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118760.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


46. Fleisch F, Reinhart WH, Brand B, Berger C: Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma. Swiss Med Wkly; 2005 Apr 30;135(17-18):263-5
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
  • Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders.
  • Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.
  • [MeSH-major] DNA, Viral / blood. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Anti-HIV Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Prednisone / administration & dosage. Switzerland. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965829.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


47. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther; 2007;12(6):931-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
  • OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.
  • METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.
  • We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.
  • Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months).
  • Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]).
  • The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


48. Navarro JT, Vall-Llovera F, Mate JL, Morgades M, Feliu E, Ribera JM: Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica; 2008 Jan;93(1):149-50
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART.
  • We evaluated the frequency of primary central nervous system lymphoma and leptomeningeal involvement in systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / prevention & control. Meninges / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Prognosis. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166804.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


49. Chanan-Khan A, Holkova B, Goldenberg AS, Pavlick A, Demopoulos R, Takeshita K: Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases. Leuk Lymphoma; 2005 Aug;46(8):1189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases.
  • Breast involvement with non-Hodgkin's lymphoma (NHL) is rare.
  • Patients with AIDS have an increased incidence of NHL, often with high-grade histology, extranodal presentation and aggressive clinical course.
  • Lymphoma of the breast in patients with HIV-1 infection has not been reported.
  • We reviewed our tumor registry database of all AIDS-associated NHL and report on the clinical presentation and long-term outcome of 3 patients with AIDS who presented with lymphomatous involvement of the breast.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms, Male / complications. HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Antigens, CD / biosynthesis. Disease Progression. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction / methods. Treatment Outcome


50. Adler DH: The impact of HAART on HPV-related cervical disease. Curr HIV Res; 2010 Oct;8(7):493-7
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of HAART on HPV-related cervical disease.
  • PURPOSE OF REVIEW: highly active antiretroviral therapy (HAART) has had an unequivocally positive impact on morbidity and mortality in HIV-infected individuals.
  • These benefits have clearly extended to some HIV-related malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • The objective of this review is to summarize the last ten years of registry-based and clinical research into the impact of HAART on human papillomavirus (HPV) related cervical disease.
  • RELEVANT FINDINGS: compared to their HIV-uninfected counterparts, HIV-infected women have an increased prevalence of HPV infection, increased risk of progression of HPV-related cervical disease, and an increased risk of invasive cervical cancer.
  • While the partial immune reconstitution afforded by HAART might be expected to decrease susceptibility to HPV infection and cervical disease, the local effects of improved immunosurveillance on the cervix are uncertain and the increased longevity of patients on HAART may increase risk of exposure to HPV and provide the time required for progression of cervical disease.
  • Clinical research on the subject, however, has produced conflicting evidence with regards to both the effect of HAART on HPV infection and its impact on cervical disease progression/regression.
  • Furthermore, clinical research has not shown a clear benefit of HAART in decreasing HPV-related cervical disease in HIV-infected women.
  • A better understanding of this subject will have an impact on cervical disease surveillance practices.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2000 Sep;96(3):403-9 [10960634.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38(5):737-42 [14986260.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Infect Dis. 2001 Sep 1;184(5):547-51 [11494160.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42 [11511819.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] AIDS. 2002 Apr 12;16(6):927-9 [11919496.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Infect Dis Obstet Gynecol. 2002;10(1):3-64 [12090361.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1799-802 [12218392.001]
  • [Cites] J Infect Dis. 2003 Jul 1;188(1):128-36 [12825181.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71 [12865452.001]
  • [Cites] Curr Opin Oncol. 2003 Sep;15(5):382-8 [12960521.001]
  • [Cites] AIDS. 2003 Sep 26;17(14):2136-8 [14502023.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):225-31 [14751163.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):418-24 [14961581.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] JAMA. 1993 Feb 10;269(6):729-30 [8093740.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1343-9 [9358128.001]
  • [Cites] AIDS. 1998 Aug 20;12(12):1459-64 [9727566.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Braz J Infect Dis. 2004 Oct;8(5):356-62 [15798811.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2337-44 [17117020.001]
  • [Cites] Antivir Ther. 2006;11(8):1091-6 [17302379.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1908-10 [17494923.001]
  • [Cites] Acta Biomed. 2007;78(1):36-40 [17687815.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):470-5 [17762573.001]
  • [Cites] J Antimicrob Chemother. 2008 Jan;61(1):191-4 [17977910.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Eur J Cancer Prev. 2008 Nov;17(6):545-54 [18941376.001]
  • [Cites] Obstet Gynecol. 2009 Jan;113(1):26-31 [19104356.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):840-7 [19223894.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):274-82 [19387354.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1775-84 [10985315.001]
  • (PMID = 20946095.001).
  • [ISSN] 1873-4251
  • [Journal-full-title] Current HIV research
  • [ISO-abbreviation] Curr. HIV Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI078498-01; United States / NIAID NIH HHS / AI / K23 AI077759; United States / NIAID NIH HHS / AI / P30 AI078498; United States / NIAID NIH HHS / AI / P30 AI078498-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS293555; NLM/ PMC3108243
  •  go-up   go-down


51. Hernàndez DE, Hernàndez AE: Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Eur J Cancer Care (Engl); 2006 Dec;15(5):493-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
  • The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin's lymphoma (NHL) patients is very expensive in developing countries.
  • We treated 22 HIV-associated diffuse NHL patients with standard-dose CHOP and used G-CSF after an episode of febrile neutropenia until neutrophil count reached 1000/mm3.
  • The clinical response was: complete response (36%), partial response (32%), stable disease (14%) and progression (18%).
  • There were no toxicity-related deaths.
  • Our experience showed that we can treat HIV-related NHL patients with full-dose CHOP, achieve good responses and have an acceptable toxicity profile, with the use of G-CSF as needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177909.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Corti M, Villafañe MF, Souto L, Schtirbu R, Narbaitz M, Soler Mde D: Burkitt's lymphoma of the duodenum in a patient with AIDS. Rev Soc Bras Med Trop; 2007 May-Jun;40(3):338-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.
  • Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.
  • Most non-Hodgkin's lymphoma cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.
  • We report a case of primary lymphoma of the duodenum in a patient with AIDS.
  • A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653472.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


53. Balsalobre P, Díez-Martín JL, Re A, Michieli M, Ribera JM, Canals C, Rosselet A, Conde E, Varela R, Cwynarski K, Gabriel I, Genet P, Guillerm G, Allione B, Ferrant A, Biron P, Espigado I, Serrano D, Sureda A: Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol; 2009 May 1;27(13):2192-8
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.
  • PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.
  • Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT.
  • RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).
  • At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease.
  • CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).
  • Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively).
  • CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263
  • (PMID = 19332732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Tisdale G, Mahadevan A, Matthews RH: T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion. Oncologist; 2005 Apr;10(4):292-8
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
  • Primary T-cell non-Hodgkin's lymphoma (NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.
  • Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.
  • In addition, the patient suffered from concomitant cirrhosis related to hepatitis C.
  • Chemotherapeutic options for ARL were limited early in the AIDS epidemic due to poor tolerability.
  • Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his lymphoma or AIDS, that ultimately brought about his demise.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821249.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G, Mortality 2000 study group: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol; 2005 Feb;34(1):121-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
  • BACKGROUND: In the era of highly active antiretroviral therapy (HAART) mortality has decreased substantially among human immunodeficiency virus (HIV)-infected people with access to HAART, but there are concerns regarding co-morbidities and adverse effects of HAART, which may impair vital prognosis.
  • The Mortality 2000 study examined the causes of death in HIV-infected adults at a national level in France in the year 2000.
  • METHODS: All French hospital wards known to be involved in the management of HIV infection were asked to notify prospectively the deaths that occurred in 2000 among HIV-infected adults.
  • The main underlying causes of death were AIDS-related (47%, non-Hodgkin's lymphoma: 23%), viral hepatitis (11%, hepatitis C: 9%, hepatitis B: 2%), cancer not related to AIDS or hepatitis (11%), cardiovascular disease (7%), bacterial infections (6%), suicide (4%), and adverse effect of antiretroviral treatments (1%).
  • Among AIDS-related deaths, HIV infection had been diagnosed recently in 20%.
  • Smoking was recorded in 72% of cancer-related deaths and alcohol consumption in 54% of hepatitis-related deaths.
  • Among non-HIV related deaths between 25 and 64 years, the proportion of infectious diseases (including HCV and HBV-related deaths) was higher in HIV-infected adults than in the general population.
  • CONCLUSIONS: Improved strategies for detecting HIV infection before AIDS-defining complications occur are needed in the era of HAART.
  • The prevention of non-AIDS related cancers, especially lung cancer, the management of non-Hodgkin's lymphoma, and of viral hepatitis are also important priorities.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Hepatitis, Viral, Human / mortality. Neoplasms / mortality


56. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • MATERIALS AND METHODS: We have retrospectively reviewed records of NHL patients registered, from January 2003 to July 2007 to analyze HIV-associated NHL.
  • RESULTS: Seven cases of HIV-associated NHL cases were identified.
  • Three cases had nodal lymphoma and four had extra nodal lymphoma.
  • No primary CNS (PCNSL) lymphoma was seen.
  • HIV infection was diagnosed as part of NHL work-up in five patients.
  • RESPONSE: One patient achieved complete response (CR) and continues to be disease free, with 4.5 years of follow-up.
  • Three cases achieved partial response (PR) and 2 had progressive disease (PD).
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology


57. Malhotra P, Shah SS, Kaplan M, McGowan JP: Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin. J Infect; 2005 Oct;51(3):e181-3
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin.
  • We present a case of a patient with multiple risk factors for fungemia including HIV infection, Hodgkin's disease, corticosteroid use and chemotherapy-induced neutropenia who developed disseminated cryptococcal infection while receiving caspofungin.
  • [MeSH-major] Antifungal Agents / therapeutic use. Cryptococcus neoformans / isolation & purification. Fungemia / complications. HIV Infections / complications. Neutropenia / complications. Peptides, Cyclic / therapeutic use
  • [MeSH-minor] AIDS-Related Opportunistic Infections / microbiology. Cryptococcosis / complications. Cryptococcosis / microbiology. Drug Resistance, Fungal. Echinocandins. Hodgkin Disease / complications. Humans. Mycoses / prevention & control

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230203.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


58. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic non-Hodgkin's lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD.
  • Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.
  • Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology


59. Gujral S, Gandhi JS, Valsangkar S, Shet TM, Epari S, Subramanian PG: Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):723-8
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy.
  • AIMS: Study of the morphological patterns of acquired immunodeficiency syndrome (AIDS)-related lymphadenopathy.
  • SETTINGS AND DESIGN: We retrospectively selected cases of AIDS-related benign lymphadenopathy.
  • We analyzed different morphological patterns and correlated these with immunophenotypic markers along with viral markers human herpesvirus 8-latency-associated nuclear antigen (HHV8-LANA), and Epstein-Barr virus-encoded ribonucleic acid (EBER) studies via in situ hybridization (EBER-ISH).
  • MATERIALS AND METHODS: We present the morphological patterns of 13 cases of human immunodeficiency virus (HIV)-reactive lymph nodes and their clinical, hematological, biochemical and radiological parameters with special emphasis on the presence or absence of viral markers, including HHV8 and EBV.
  • Two cases of multicentric Castleman's disease expressed EBER; however, they did not express HHV8.
  • CONCLUSION: The wide spectrum of histological changes in HIV-associated lymphadenopathy requires recognition.
  • The histological changes can mimic those of other infective lymphadenitis, follicular lymphoma, Castleman's disease, progressive transformation of germinal center, Hodgkin's disease and spindle cell neoplasms.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Epstein-Barr Virus Infections / pathology. HIV Infections / complications. Herpesviridae Infections / pathology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Lymphatic Diseases / pathology


60. Collins LS, Fowler A, Tong CY, de Ruiter A: Multicentric Castleman's disease in HIV infection. Int J STD AIDS; 2006 Jan;17(1):19-24; quiz 25
HIV InSite. treatment guidelines - Pneumocystosis and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease in HIV infection.
  • Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder.
  • The precise incidence is unknown, although it is more common in HIV-positive than HIV-negative individuals.
  • The pathological features of MCD strongly suggest a chronic antigen stimulation response, and human herpes virus 8 (HHV8) has been found to be universal in cases of HIV-related MCD.
  • Randomized control trials assessing whether 'prophylactic' treatment with ganciclovir may prevent flares as currently used against cytomegalovirus disease in transplant patients are proposed.
  • The prognosis of MCD in HIV-positive patients remains generally poor with a median survival of 48 months from diagnosis, and a 15-fold increased risk of non-Hodgkin's lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia. HIV Infections / complications
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. HIV-1. Herpesvirus 8, Human. Humans. Male


61. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • To date, no prognostic factor has been identified in this subset of lymphoma.
  • PATIENTS AND METHODS: We describe here a large series of HIV-infected patients with PEL, including 28 cases diagnosed in six centers during an 11-year time period.
  • Fourteen patients (50%) achieved complete remission, with a 1-year disease-free survival rate at 78.6%.
  • CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-related PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human. Lymphoma, AIDS-Related / mortality


62. Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U: Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol; 2009 May;81(5):888-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
  • This is a mono-institutional analysis of the clinical features, immunological and virological findings, and prognostic factors of patients with HIV infection and HHV-8-lymphoproliferative disorders.
  • Patients with Multicentric Castleman Disease and HHV-8-related lymphoma diagnosed and treated from April 1987 to June 2004 were included in the study.
  • HHV-8 and HIV plasma viral load, CD4+ count, hematologic parameters, and general wellbeing (performance status) were assessed at the onset of the diseases and analyzed in order to identify possible prognostic factors.
  • Nine patients with Multicentric Castleman disease, and 16 with HHV-8-related lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-related non-Hodgkin's lymphomas.
  • Four patients with Multicentric Castleman disease received only antiretroviral drugs; 5 HAART plus oral etoposide.
  • Nine patients with primary effusion lymphoma were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.
  • The patients with solid lymphoma underwent CHOP-like chemotherapy.
  • Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-related lymphomas.
  • In the univariate analysis, HHV-8-related lymphoma, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.
  • Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival.
  • [MeSH-major] HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / complications. Viral Load
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / virology. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


63. Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E: A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease. AIDS; 2008 Feb 19;22(4):539-40
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease.
  • A 44-year-old man with relapsed HIV-associated stage IV nodular sclerosing Hodgkin's disease underwent high-dose therapy with autologous stem cell transplantation.
  • Autologous stem cell transplantation is safe in HIV patients and can achieve long-term durable remissions in Hodgkin's disease.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301069.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


64. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, Minarovits J: The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis; 2009;1(2):e2009012
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
  • Epstein-Barr virus (EBV), a human gammaherpesvirus, is associated with a series of malignant tumors.
  • These include lymphomas (Burkitt's lymphoma, Hodgkin's disease, T/NK-cell lymphoma, post-transplant lymphoproliferative disease, AIDS-associated lymphoma, X-linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, gastric carcinoma, carcinomas of major salivary glands, thymic carcinoma, mammary carcinoma) and a sarcoma (leiomyosarcoma).
  • Based on the cell type specific epigenetic marks associated with latent EBV genomes one can distinguish between viral epigenotypes that differ in transcriptional activity in spite of having an identical (or nearly identical) DNA sequence.
  • EBNA3C (EBNA6) seems to be associated both with histone acetylases and deacetylases, although in separate complexes.
  • In epithelial cells LMP1 can up-regulate DNA methyltransferases and, in Hodgkin lymphoma cells, induce the Polycomb group protein Bmi-1.
  • Elucidation of the epigenetic consequences of EBV-host interactions (within the framework of the emerging new field of patho-epigenetics) may have important implications for therapy and disease prevention, because epigenetic processes are reversible and continuous silencing of EBV genes contributing to patho-epigenetic changes may prevent disease development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2287-91 [1594447.001]
  • [Cites] J Gen Virol. 1992 Jul;73 ( Pt 7):1687-92 [1321209.001]
  • [Cites] Virology. 1994 May 1;200(2):661-7 [8178450.001]
  • [Cites] J Virol. 1994 Sep;68(9):5375-83 [8057421.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6150-9 [7565767.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3129-36 [8874213.001]
  • [Cites] J Virol. 1997 Mar;71(3):1938-45 [9032325.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] J Mol Biol. 2005 Jul 22;350(4):631-40 [15967459.001]
  • [Cites] Am J Hematol. 2006 Jan;81(1):5-11 [16369970.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2995-3002 [16707594.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Bacteriol. 2006 Dec;188(23):8160-8 [16997949.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5722-35 [10891508.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Mar;75(6):2584-96 [11222681.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):469-76 [11669609.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):442-3 [17392803.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] J Virol. 2007 Dec;81(23):13242-7 [17898065.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] J Virol. 2002 May;76(10):4699-708 [11967287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4035-40 [12427740.001]
  • [Cites] J Virol. 2003 Apr;77(7):4261-72 [12634383.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1443-50 [12771413.001]
  • [Cites] J Virol. 2003 Jul;77(14):8166-72 [12829856.001]
  • [Cites] Virus Genes. 2003 Aug;27(1):57-66 [12913358.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19278-83 [17159145.001]
  • [Cites] J Gen Virol. 2008 Jun;89(Pt 6):1364-70 [18474551.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] J Virol. 2009 Apr;83(7):2930-40 [19129441.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Virol. 2009 Jul;83(14):7109-16 [19403674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):430-5 [10618435.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2343-9 [10713158.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):131-7 [11801549.001]
  • [Cites] Adv Cancer Res. 2003;89:133-56 [14587872.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Trends Microbiol. 2004 Nov;12(11):495-9 [15488390.001]
  • [Cites] J Virol. 2004 Nov;78(22):12308-19 [15507618.001]
  • [Cites] Science. 1980 Nov 7;210(4470):604-10 [6254144.001]
  • [Cites] J Virol. 1983 May;46(2):446-53 [6302313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] J Virol. 1998 Sep;72(9):7075-83 [9696800.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):46-56 [9858530.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Gene. 1999 Aug 5;236(1):87-95 [10433969.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] J Virol. 2004 Dec;78(24):14062-5 [15564516.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):542-52 [15706033.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):286-95 [15959556.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):344-53 [15959560.001]
  • [Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]
  • [Cites] Nature. 1986 May 15-21;321(6067):209-13 [2423876.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] Adv Cancer Res. 1988;50:95-158 [2837072.001]
  • [Cites] Cell. 1988 Jul 1;54(1):127-35 [2838178.001]
  • [Cites] Cell. 1988 Nov 4;55(3):427-33 [2846181.001]
  • [Cites] J Mol Biol. 1988 Oct 20;203(4):971-83 [3210246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(17):6498-502 [2549539.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):179-87 [1968655.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):285-97 [1968665.001]
  • [Cites] J Virol. 1990 Nov;64(11):5295-300 [2170673.001]
  • [Cites] EMBO J. 1991 Jan;10(1):143-51 [1846596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942-6 [1850841.001]
  • [Cites] J Virol. 1992 Jan;66(1):62-9 [1370095.001]
  • [Cites] J Gen Virol. 1991 Dec;72 ( Pt 12):3025-33 [1662694.001]
  • (PMID = 21416002.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033174
  •  go-up   go-down


65. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV: the Indian scenario.
  • PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.
  • With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.
  • The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.
  • RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.
  • Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.
  • The incidence of AIDS-related primary central nervous system lymphoma is low in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
  • As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


66. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic complications of HIV infection.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • Thrombotic thrombocytopenic purpura and thrombosis resulting from protein S deficiency are relatively rare complications of HIV in the United States in patients taking HAART, but are frequent in the developing world where these drugs are not available.
  • Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads.
  • This review will examine and discuss the diagnosis and management of the hematologic complications of HIV.
  • [MeSH-major] HIV Infections / complications. Hematologic Diseases / etiology
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


67. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GI-lymphomas in immunosuppressed patients (organ transplantation; HIV).
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


68. Makin E, Davenport M: Idiopathic biliary perforation in a 10-year-old boy. Pediatr Surg Int; 2006 May;22(5):465-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 10-year-old boy of African origin with AIDS and Stage IV Hodgkin's lymphoma presented with a short history of abdominal distension and bile ascites shown to be due to a perforation of his common bile duct.
  • Although the co-morbid conditions are likely to be contributory factors, biliary perforation in either disease has not been reported before.
  • [MeSH-minor] Child. Cholangiopancreatography, Endoscopic Retrograde. Comorbidity. Hodgkin Disease / epidemiology. Humans. Lymphoma, AIDS-Related / epidemiology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Surg. 1983 Sep;13(5):441-5 [6668781.001]
  • [Cites] Br J Surg. 1991 Sep;78(9):1068-70 [1933187.001]
  • [Cites] J Pediatr Surg. 2006 Sep;41(9):1539-44 [16952588.001]
  • [Cites] J Pediatr Surg. 1993 Jul;28(7):950-2 [8229576.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1991 Apr;12(3):379-82 [2072232.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6(6):341-6 [9007467.001]
  • [Cites] Arch Surg. 2004 Oct;139(10):1083-7 [15492148.001]
  • [Cites] Asian J Surg. 2004 Oct;27(4):342-4 [15564193.001]
  • [Cites] J Pediatr Surg. 1988 Feb;23(2):185-7 [3278089.001]
  • [Cites] Surgery. 1974 May;75(5):664-73 [4824426.001]
  • [Cites] J Pediatr Surg. 1996 Dec;31(12 ):1721-3 [8987001.001]
  • [Cites] Gastrointest Endosc. 1998 Dec;48(6):623-6 [9852455.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Nov;35(5):669-73 [12454584.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):541-6 [894454.001]
  • (PMID = 16450146.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Iwahashi N, Nakatani S, Kakuchi H, Yamagishi M, Fukuchi K, Ishida Y, Hirooka K, Koretsune Y, Ueta C, Shirasaka T, Kitakaze M: Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J; 2005 Feb;69(2):243-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cardiac tumor was the first manifestation of acquired immunodeficiency syndrome (AIDS) in a female patient in a state of severe immunodeficiency caused by human immunodeficiency virus (HIV) infection.
  • The extensive cardiac and extracardiac involvement shown by various imaging modalities, including echocardiography and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), suggested that she was in the critical stage of non-Hodgkin's lymphoma (NHL).
  • AIDS was treated by highly active-antiretroviral therapy and the NHL was treated by a combination of rituximab-cyclophosphamide-vincristine-doxorubicine-predonisolone.
  • Generally, an AIDS-related cardiac tumor tends to be diagnosed at the late stage of the disease because of its nonspecific clinical findings, resulting in an extremely poor prognosis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671621.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


70. Radhakrishnan R, Suhas S, Kumar RV, Krishnanand G, Srinivasan R, Rao NN: Plasmablastic lymphoma of the oral cavity in an HIV-positive child. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Dec;100(6):725-31
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity in an HIV-positive child.
  • A 7-year-old boy with a positive history of vertical HIV transmission presented with a painful swelling over the left upper jaw of 20 days' duration.
  • A provisional diagnosis of non-Hodgkin's lymphoma or embryonal rhabdomyosarcoma was made.
  • The heterogeneous presentation of plasmablastic lymphoma as a variant of diffuse large B-cell lymphoma and its histogenesis is documented.
  • Potential pitfalls and differential characterization of AIDS-plasmablastic lymphoma from other closely related tumors are addressed.
  • To the best of our knowledge, this is the first report of this entity in a vertically transmitted HIV-positive child.
  • [MeSH-major] HIV Seropositivity / complications. Lymphoma, AIDS-Related / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Maxillary Neoplasms / etiology
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Immunoglobulin lambda-Chains / analysis. Infectious Disease Transmission, Vertical. Male. Membrane Glycoproteins / analysis. Proteoglycans / analysis. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301154.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin lambda-Chains; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


71. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transplantation. 2006 Jun 27;81(12):1752-3 [16794547.001]
  • (PMID = 16177644.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


72. Serrano D, Miralles P, Balsalobre P, Díez-Martin JL, Berenguer J: Hematopoietic stem cell transplantation in patients infected with HIV. Curr HIV/AIDS Rep; 2010 Aug;7(3):175-84
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in patients infected with HIV.
  • Hematopoietic stem cell transplantation (HSCT) replaces a diseased hematopoietic system with a functional, disease-free graft and is frequently used in the treatment of hematologic malignancies.
  • The advent of highly active antiretroviral therapy made it possible to treat medical conditions in HIV-infected patients in the same way as in the general population.
  • Several studies have reported the feasibility, safety, and efficacy of autologous HSCT as rescue or consolidation treatment for non-Hodgkin's and Hodgkin's lymphoma in HIV-infected patients.
  • As a result of the improvements in supportive care and the introduction of attenuated transplant conditioning regimens, allogeneic HSCT has been used to treat life-threatening hematologic disorders, with promising results in HIV-infected patients.
  • Moreover, this strategy has made it possible to treat both the hematologic disease and HIV infection.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Hodgkin Disease / complications. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549392.001).
  • [ISSN] 1548-3576
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


73. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphomas (ML) and HIV infection in Tanzania.
  • BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
  • The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
  • METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.
  • Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were HIV positive.
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
  • The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]
  • [Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]
  • [Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]
  • [Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]
  • [Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]
  • [Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]
  • [Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]
  • [Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]
  • [Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]
  • (PMID = 18577266.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2438337
  •  go-up   go-down


74. Wang J, Ozzard A, Nathan M, Atkins M, Nelson M, Gazzard B, Bower M: The significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV infection. HIV Med; 2007 Jul;8(5):306-11
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV infection.
  • INTRODUCTION: Epstein-Barr virus (EBV) is detected in the cerebrospinal fluid (CSF) in people with HIV infection who develop primary cerebral lymphoma (PCL).
  • METHODS: Ninety-eight HIV-positive patients had lumbar punctures performed and polymerase chain reaction (PCR) for EBV was undertaken on the CSF.
  • Thirty-eight patients had non-Hodgkin's lymphoma (NHL), including four with PCL.
  • RESULTS: EBV was detected in the CSF in three of four patients (75%) with PCL, one of three (33%) with systemic lymphoma and meningeal involvement, and four of 31 (13%) with systemic lymphoma and no meningeal disease.
  • Seven of 60 patients (12%) without lymphoma were CSF EBV-positive.
  • CONCLUSION: EBV was detected in up to 12% of patients with neurological symptoms but without lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / cerebrospinal fluid. HIV / growth & development. HIV Infections / cerebrospinal fluid. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561877.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


75. Butt FM, Chindia ML, Rana F, Machigo FG: Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya. Int J Oral Maxillofac Surg; 2008 Oct;37(10):907-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya.
  • HIV-infected patients face a greater risk of developing malignant disease.
  • The most commonly reported neoplasms of the head and neck region include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL).
  • A descriptive cross-sectional study including HIV-infected patients with neoplastic and non-neoplastic lesions was conducted.
  • The prevalence of neoplastic lesions in this study was 27%; 37 (68%) patients had KS, 9 (17%) had SCC, 7 (13%) had NHL and 1 (2%) had Burkitt's lymphoma.
  • Most study participants (97%) were in stage III/IV of the disease and the remaining 3% in stage II.
  • In this study, the most common malignant neoplasms were KS, SCC and NHL, manifesting in a younger age group than in the non-HIV group of patients.
  • [MeSH-major] HIV Infections / epidemiology. Head and Neck Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Burkitt Lymphoma / epidemiology. Candidiasis, Oral / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Prevalence. Sarcoma, Kaposi / epidemiology. Sex Factors. Stomatitis, Aphthous / epidemiology. Young Adult


76. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we highlight two cases in which the cytogenetic studies challenge the common practice of using hematologic and morphologic changes as key factors in malignant disease management.
  • The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's lymphoma (NHL) patient sent for determination of disease progress.
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade lymphoma.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Sparano JA: HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol; 2007 Sep;19(5):458-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma: the evidence for treating aggressively but with caution.
  • PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year.
  • RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • Emerging evidence suggests that patients with HIV-associated lymphoma should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.
  • Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell lymphoma, but may come at the expense of an increased risk of bacterial and viral infections.
  • SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated lymphoma, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] HIV. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


78. van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM, Grulich AE: Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ; 2010;340:c570
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Standardised incidence ratios were significantly elevated during transplant function, but not during dialysis after transplant failure, for non-Hodgkin's lymphoma, lip cancer, and melanoma.
  • For each of these cancers, incidence was significantly lower during dialysis after transplant failure in multivariate analysis (incidence rate ratios 0.20 (95% CI 0.06 to 0.65) for non-Hodgkin's lymphoma, 0.04 (0.01 to 0.31) for lip cancer, and 0.16 (0.04 to 0.64) for melanoma).
  • In contrast, standardised incidence ratios during dialysis after transplant failure remained significantly elevated for leukaemia and lung cancer, and cancers related to end stage kidney disease (kidney, urinary tract, and thyroid cancers), with thyroid cancer incidence significantly higher during dialysis after transplant failure (incidence rate ratio 6.77 (2.64 to 17.39)).
  • Risk of other cancers, especially those related to end stage kidney disease, remained significantly increased after reduction of immunosuppression.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2001 May;67(5):397-9 [11379634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2297-303 [19622722.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Int J Epidemiol. 1989 Mar;18(1):45-9 [2722382.001]
  • [Cites] N Engl J Med. 1989 Oct 19;321(16):1080-5 [2552313.001]
  • [Cites] Cancer Detect Prev. 1994;18(4):241-52 [7982234.001]
  • [Cites] Am J Nephrol. 1998;18(2):89-95 [9569948.001]
  • [Cites] Springer Semin Immunopathol. 1998;20(3-4):343-55 [9870250.001]
  • [Cites] Proc R Soc Med. 1965 May;58:295-300 [14283879.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):338-40 [16443071.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Transplant Rev (Orlando). 2008 Jan;22(1):62-72 [18631859.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] Transplantation. 2008 Sep 15;86(5):738-44 [18791457.001]
  • [Cites] Transplant Rev (Orlando). 2008 Oct;22(4):252-61 [18656341.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):561-9 [19190169.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Blood. 2009 Jul 16;114(3):630-7 [19443660.001]
  • [Cites] Am J Kidney Dis. 2002 Dec;40(6):1122-31 [12460029.001]
  • (PMID = 20150194.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820609
  •  go-up   go-down


79. Svec MA, Ward MH, Dosemeci M, Checkoway H, De Roos AJ: Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public. Occup Environ Med; 2005 Oct;62(10):726-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To conduct a population based, case-control study of death certificate data from 1984 to 1998 in 24 US states in order to evaluate the risk of mortality from LH neoplasms associated with occupational exposure to animals or the public.
  • METHODS: Cases were selected as those with an underlying cause of death of non-Hodgkin's lymphoma (NHL, n = 72,589), Hodgkin's disease (HD, n = 5479), multiple myeloma (n = 35,857), or leukaemia (n = 68,598); 912 615 controls were randomly selected from all remaining deaths, frequency matched on age, sex, race, and geographic region.
  • RESULTS: Occupational exposure to animals was associated with modest increased risks of mortality from all four LH cancers; these associations varied by region.
  • Occupational exposure to the public was associated with only negligible increased risk with LH cancer outcomes.
  • Occupations involving animal exposure were predominantly agricultural, and the risks associated with employment in the livestock industry exceeded the corresponding risks associated with the crop industry for all outcomes except HD.
  • CONCLUSIONS: Increased risks of NHL, HD, multiple myeloma, and leukaemia were associated with occupations that involved animal exposure.
  • Regional differences in risk imply that the risks may be associated with exposure to specific livestock or farming practices.
  • However, these associations may be confounded by other farming related exposures, such as pesticides.
  • [MeSH-minor] Animals. Case-Control Studies. Death Certificates. Disease Transmission, Infectious. Humans. Leukemia / etiology. Leukemia / microbiology. Lymphoma / etiology. Lymphoma / microbiology. Registries. Retrospective Studies. Risk Factors. United States / epidemiology. Zoonoses

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Work Environ Health. 1999 Feb;25(1):5-17 [10204665.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):60-9 [10361588.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):155-8 [10361601.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):159-65 [10361602.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):186-92 [10361605.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Invest. 2000;18(4):366-80 [10808373.001]
  • [Cites] Cancer Invest. 2000;18(5):467-79 [10834031.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):78-87 [11138825.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):135-9 [11458277.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):509-17 [11519759.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):635-43 [11552711.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):657-9 [11956646.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):78-9 [12110734.001]
  • [Cites] Cancer Causes Control. 2002 Aug;13(6):563-71 [12195646.001]
  • [Cites] Am J Ind Med. 2002 Aug;Suppl 2:54-61 [12210683.001]
  • [Cites] Am J Ind Med. 2002 Nov;42(5):410-20 [12382254.001]
  • [Cites] J Occup Environ Med. 2003 Aug;45(8):857-68 [12915787.001]
  • [Cites] Eur J Cancer Prev. 2003 Dec;12(6):517-26 [14639130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30 [15006919.001]
  • [Cites] Epidemiology. 2004 May;15(3):352-6 [15097020.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):713-24 [15158093.001]
  • [Cites] Scand J Work Environ Health. 2004 Jun;30(3):215-22 [15250650.001]
  • [Cites] Public Health Rep. 1970 Sep;85(9):815-27 [4989476.001]
  • [Cites] Am J Epidemiol. 1971 Oct;94(4):507-10 [5165015.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):45-9 [4858064.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1489-91 [857036.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Ann Intern Med. 1978 Oct;89(4):550-6 [697236.001]
  • [Cites] Am J Epidemiol. 1980 Jul;112(1):80-92 [6930819.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Am J Epidemiol. 1982 May;115(5):720-8 [7081203.001]
  • [Cites] Int J Epidemiol. 1982 Dec;11(4):391-7 [7152791.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1017-9 [6412930.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):251-5 [6582313.001]
  • [Cites] Am J Ind Med. 1984;6(2):97-102 [6465143.001]
  • [Cites] Am J Ind Med. 1984;6(3):185-205 [6475965.001]
  • [Cites] Am J Epidemiol. 1985 May;121(5):675-83 [4014159.001]
  • [Cites] Br J Ind Med. 1986 Feb;43(2):75-83 [3753879.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):402-9 [3740040.001]
  • [Cites] Br J Cancer. 1986 Sep;54(3):493-500 [3756085.001]
  • [Cites] Int J Cancer. 1987 Feb 15;39(2):155-61 [3804490.001]
  • [Cites] Am J Vet Res. 1987 Feb;48(2):235-8 [3030166.001]
  • [Cites] Am J Epidemiol. 1987 Dec;126(6):1051-62 [3687917.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):25-8 [3342184.001]
  • [Cites] Am J Ind Med. 1988;13(3):317-30 [3354583.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2919-22 [2834051.001]
  • [Cites] J Occup Med. 1989 Mar;31(3):270-2 [2918412.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3605-9 [2340508.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Br J Ind Med. 1992 Feb;49(2):95-103 [1536825.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Br J Ind Med. 1993 Jan;50(1):79-84 [8431395.001]
  • [Cites] Am J Ind Med. 1993 May;23(5):729-42 [8506851.001]
  • [Cites] Soc Sci Med. 1993 Sep;37(6):771-7 [8211293.001]
  • [Cites] Am J Epidemiol. 1994 Mar 15;139(6):609-19 [8172172.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] J Occup Med. 1994 Nov;36(11):1210-21 [7861265.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Am J Ind Med. 1995 Jun;27(6):817-35 [7645576.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):154-61 [7577624.001]
  • [Cites] Lancet. 1996 Mar 2;347(9001):624-5 [8596360.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Scand J Soc Med. 1996 Jun;24(2):114-20 [8816000.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):754-8 [8980179.001]
  • [Cites] Vet Clin North Am Food Anim Pract. 1997 Mar;13(1):177-90 [9071753.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Am J Public Health. 1997 Sep;87(9):1539-43 [9314812.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1142-50 [9447392.001]
  • [Cites] Am J Epidemiol. 1998 Apr 15;147(8):727-38 [9554414.001]
  • [Cites] Occup Environ Med. 1998 Aug;55(8):522-7 [9849538.001]
  • (PMID = 16169919.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1740863
  •  go-up   go-down


80. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • While not classified as AIDS-defining, these malignancies have been referred to as AIDS-associated malignancies.
  • The mechanisms by which depressed immunity could increase the risk for cancer are unclear, except for in KS and most subtypes of NHL, where it is strictly associated with a low CD4 count.
  • Although it remains unclear whether HIV-1 acts directly as an oncogenic agent, it may contribute to the development of malignancies through several mechanisms (e.g., infection by oncogenic viruses, impaired immune surveillance, imbalance between cellular proliferation and differentiation).
  • Studies of the effect of highly active antiretroviral therapy (HAART) on the incidence and progression of HIV/AIDS-associated cancers provided contrasting data.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.
  • Regardless of whether these cancers are directly related to HIV-induced immunodeficiency, treating cancer in HIV-infected patients remains a challenge because of drug interactions, compounded side effects, and the potential effect of chemotherapy on CD4 count and HIV-1 viral load.
  • A better knowledge of viral mechanisms of immune evasion and manipulation will provide the basis for a better management and treatment of the malignancies associated with chronic viral infections.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. HIV-1. Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390054.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 44
  •  go-up   go-down


81. Noy A: Update in HIV lymphoma. Curr Opin Oncol; 2006 Sep;18(5):449-55
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in HIV lymphoma.
  • PURPOSE OF REVIEW: Despite the control of HIV infection in industrialized nations, individuals infected with HIV remain at increased risk of malignancies.
  • Lymphoma is the most common HIV-associated malignancy in these countries.
  • RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.
  • The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation.
  • The latter improves complete response rates, but is associated with an increased incidence of infections.
  • Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.
  • SUMMARY: The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894292.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 45
  •  go-up   go-down


82. Marotta D, Sgambato A, Cerciello S, Magarelli N, Martini M, Larocca LM, Maccauro G: Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World J Surg Oncol; 2008;6:111
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.
  • BACKGROUND: The risk of developing lymphoma is greatly increased in HIV infection.
  • Musculoskeletal manifestations of the human immunodeficiency virus (HIV) are common and are sometimes the initial presentation of the disease.
  • HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.
  • In March 2004 she was diagnosed HIV positive and contemporary got pregnant.
  • A final diagnosis of diffuse large B-cell lymphoma was made.
  • HIV infection is still under control.
  • CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.
  • Authors want to underline this case for the rare position, the big size and the association with HIV infection.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Pregnancy. Risk Assessment. Shoulder. Surgical Procedures, Operative / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]
  • [Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]
  • [Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]
  • [Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]
  • [Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]
  • [Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]
  • [Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]
  • [Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]
  • (PMID = 18939988.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


83. Lan K, Verma SC, Murakami M, Bajaj B, Robertson ES: Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol; 2007 Aug;Chapter 14:Unit 14E.2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) was first reported as the etiological agent of Burkitt's lymphoma in 1964.
  • Since then, EBV has also been associated with nasopharyngeal carcinoma, which is highly prevalent in Southeast Asia, as well as infectious mononucleosis, complications of AIDS, and transplant-related B cell lymphomas.
  • This virus has further been linked with T cell lymphomas and Hodgkin's disease, establishing the concept of a wide spectrum of EBV-associated malignant disorders.
  • So far, there are a number of EBV-infected cell lines established that can be induced for production of infectious viral progeny and that facilitate the study of the mechanism of EBV-related infection, transformation, and oncogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770612.001).
  • [ISSN] 1934-8533
  • [Journal-full-title] Current protocols in microbiology
  • [ISO-abbreviation] Curr Protoc Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


84. Krentz HB, Kliewer G, Gill MJ: Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med; 2005 Mar;6(2):99-106
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
  • OBJECTIVES: To examine changes over a 2-year period in both the mortality rate and the causes of death in a geographically defined HIV-infected population.
  • METHODS: A database search of primary care information for the dates and causes of death for all patients documented with HIV infection and living in Southern Alberta between 1984 and 2003 was undertaken.
  • AIDS deaths were reconciled with Public Health Reports.
  • RESULTS: Between 1984 and 2003, there were 560 deaths in the 1987 individuals living with HIV infection in Southern Alberta.
  • In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era.
  • The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%).
  • The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era.
  • Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths.
  • A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions.
  • Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation.
  • In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
  • CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients.
  • The increasing age of the HIV population, and the increased mean CD4 count, increased proportion of intravenous drug users, increased hepatitis B virus and hepatitis C virus coinfection rate, and increased history of smoking seen in our population also influenced the mortality rate and causes of death.
  • These factors must also be considered in projecting future trends in mortality of an HIV-infected population.
  • [MeSH-major] HIV Infections / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Alberta. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Cause of Death / trends. Disease Progression. Drug Resistance, Multiple, Viral. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology. Mycobacterium avium-intracellulare Infection / mortality. Mycobacterium avium-intracellulare Infection / virology. Pneumonia, Pneumocystis / mortality. Pneumonia, Pneumocystis / virology. Socioeconomic Factors. Substance Abuse, Intravenous. Treatment Refusal


85. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving epidemiology of malignancies in HIV.
  • PURPOSE OF REVIEW: Morbidity and mortality related to malignancy are increasing in HIV-infected patients.
  • We aim at reviewing the literature on recent changes in the incidence of AIDS-defining and non-AIDS-defining malignancies and the specific characteristics of the main cancers emerging in HIV-infected patients.
  • RECENT FINDINGS: Currently, malignancies are the most frequent underlying cause of death (around one-third) of HIV-infected patients.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • The most recent and large studies have also shown a 1.7-3-fold higher risk of developing non-AIDS malignancies in HIV-infected patients as compared with the general population without a significant impact of combination antiretroviral therapy on these trends.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.
  • In addition, the poorer prognosis reported in HIV-infected patients affected by malignancies might be interpreted as a consequence of late screening or immunosuppression.
  • SUMMARY: Prevention and screening management procedures need to be assessed on the basis of specific evidence-based studies in the HIV-infected population.
  • The respective role of HIV itself, immunosuppression, and antiretrovirals as pro-oncogenic factors need to be further examined.
  • [MeSH-major] HIV Infections / complications. Neoplasms / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


86. Stein L, Urban MI, O'Connell D, Yu XQ, Beral V, Newton R, Ruff P, Donde B, Hale M, Patel M, Sitas F: The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int J Cancer; 2008 May 15;122(10):2260-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004.
  • The effect of the evolving HIV epidemic on cancer has been sparsely documented in Africa.
  • We report results on the risk of cancer associated with HIV-1 infection using data from an ongoing study.
  • A case-control analysis was used to estimate the relative risk (odds ratio, OR) of cancer types known to be AIDS defining: Kaposi's sarcoma (n = 333), non-Hodgkin lymphoma (NHL, n = 223) and cancers of the cervix (n = 1,586), and 11 cancer types possibly associated with HIV infection: Hodgkin lymphoma (n = 154), cancers of other anogenital organs (n = 157), squamous cell cancer of the skin (SCC, n = 70), oral cavity and pharynx (n = 319), liver (n = 83), stomach (n = 142), leukemia (n = 323), melanoma (n = 53), sarcomas other than Kaposi's (n = 93), myeloma (n = 189) and lung cancer (n = 363).
  • The comparison group comprised 3,717 subjects with all other cancer types and 682 subjects with vascular disease.
  • Significantly increased risks associated with HIV-1 infection were found for HIV/AIDS associated Kaposi's sarcoma (OR = 47.1, 95% CI = 31.9-69.8), NHL (OR = 5.9, 95% CI = 4.3-8.1) and cancer of the cervix (OR = 1.6, 95% CI = 1.3-2.0); Hodgkin's disease (OR = 1.6, 95% CI = 1.0-2.7), cancers of anogenital organs other than the cervix (OR = 2.2; 95% CI = 1.4-3.3) and SCC (OR = 2.6, 95% CI = 1.4-4.9) were also significantly increased.
  • No significant associations were found between HIV and any of the other cancers examined.
  • Risks for HIV-related cancers are consistent with previous studies in Africa, and are lower when compared to those observed in developed countries.
  • [MeSH-major] African Continental Ancestry Group. HIV Infections / complications. HIV-1. Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Neoplasms, Squamous Cell / epidemiology. Neoplasms, Squamous Cell / etiology. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / etiology. South Africa / epidemiology. Surveys and Questionnaires. Time Factors


87. Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ: Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry; 2010 Nov;81(11):1288-91
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progressive Multifocal Leukoencephalopathy (PML) is a demyelinating disease of the brain caused by the polyomavirus JC (JCV) in immunosuppressed people.
  • There is no cure for PML but 1-year survival has increased from 10% to 50% in HIV-infected individuals treated with highly active antiretroviral therapy.
  • Of all patients, only two were females including one who had non-Hodgkin's lymphoma and was HIV negative.
  • All 23 HIV-positive patients received highly active antiretroviral therapy, and additional experimental therapies were not associated with a better clinical outcome.

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurovirol. 2003 Jun;9(3):411-9 [12775425.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:88-92 [12709878.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1882-93 [15115835.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):1970-8 [15215217.001]
  • [Cites] Stroke. 1989 Jun;20(6):828 [2728057.001]
  • [Cites] J Neurovirol. 1998 Feb;4(1):59-68 [9531012.001]
  • [Cites] Science. 2004 Nov 19;306(5700):1380-3 [15550673.001]
  • [Cites] N Engl J Med. 2005 Jul 28;353(4):414-6 [15947082.001]
  • [Cites] J NeuroAIDS. 1996;1(4):79-88 [16873181.001]
  • [Cites] Ann Neurol. 2006 Aug;60(2):162-73 [16862584.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31 [18667930.001]
  • [Cites] AIDS. 2008 Sep 12;22(14):1759-67 [18753934.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):77-83 [19007313.001]
  • [Cites] Virology. 2009 Jan 20;383(2):173-7 [19062062.001]
  • [Cites] J Neurovirol. 2001 Aug;7(4):386-90 [11517422.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1047-52 [12684918.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:47-53 [12709872.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1443-9 [12824781.001]
  • (PMID = 20710013.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K24 NS 060950; United States / NIAID NIH HHS / AI / R01 NS/AI 041198; United States / NINDS NIH HHS / NS / NS 047029; United States / NINDS NIH HHS / NS / R01 NS041198; United States / NINDS NIH HHS / NS / R01 NS047029; United States / NINDS NIH HHS / NS / K24 NS060950
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral
  • [Other-IDs] NLM/ NIHMS266515; NLM/ PMC3077967
  •  go-up   go-down


88. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • BACKGROUND AND OBJECTIVE: Since the introduction of highly active antiretroviral therapy (HAART), the natural history of HIV infection has been altered by an increasing survival.
  • Following this, neoplastic diseases have become more common in HIV positive patients.
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • Risk factor for HIV was MSM (n=64;46%), IDUs (n=48; 34.5%) and heterosexual (n=26; 18.7%).
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


89. Lee SM, Buchler T, Bomanji J, Ramsay A, Edwards SG: Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. AIDS; 2008 Jan 2;22(1):159-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Disease Progression. Fluorodeoxyglucose F18 / metabolism. Humans. Male. Positron-Emission Tomography / methods. Thymus Gland / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090408.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antibiotics, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


90. Carbone A, Cabras A, Gloghini A: HIV-associated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers; 2007 Apr-Jun;22(2):161-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity.
  • [MeSH-major] HIV Infections / complications. HIV Infections / immunology. Hodgkin Disease / immunology. Hodgkin Disease / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549673.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4
  •  go-up   go-down


91. Spina M, Simonelli C, Tirelli U: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2007 Feb 20;25(6):e7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Humans. Male. Prednisone / therapeutic use. Prognosis. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • (PMID = 17308261.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


92. Shah BK, Subramaniam S, Peace D, Garcia C: HIV-associated primary bone marrow Hodgkin's lymphoma: a distinct entity? J Clin Oncol; 2010 Sep 20;28(27):e459-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated primary bone marrow Hodgkin's lymphoma: a distinct entity?
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. HIV Infections / complications. Hodgkin Disease / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679601.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down






Advertisement